Clinical Trials
9
Active:4
Completed:3
Trial Phases
2 Phases
Phase 1:5
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (55.6%)Phase 2
4 (44.4%)A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Kinevant Sciences GmbH
- Target Recruit Count
- 1
- Registration Number
- NCT05351554
- Locations
- 🇺🇸
Kinevant Study Site, Charleston, South Carolina, United States
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Kinevant Sciences GmbH
- Target Recruit Count
- 107
- Registration Number
- NCT05314517
- Locations
- 🇬🇧
Kinevant Study Site, London, United Kingdom
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Kinevant Sciences GmbH
- Target Recruit Count
- 227
- Registration Number
- NCT04351243
- Locations
- 🇺🇸
Banner University Medical Center, Tucson, Arizona, United States
🇺🇸HonorHealth John C. Lincoln Medical Center, Phoenix, Arizona, United States
🇺🇸HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States
Phase 1 Study With KIN-1901 in Healthy Subjects and Subjects With Ankylosing Spondylitis
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- Kinevant Sciences GmbH
- Target Recruit Count
- 36
- Registration Number
- NCT04205851
- Locations
- 🇨🇦
Altasciences Clinical Research, Montréal, Quebec, Canada
News
No news found